Trends of nonoccupational postexposure prophylaxis in the United States

被引:1
作者
McCormick, Carter D. [1 ,5 ]
Sullivan, Patrick S. [2 ]
Qato, Dima M. [3 ,4 ]
Crawford, Stephanie Y. [1 ]
Schumock, Glen T. [1 ]
Lee, Todd A. [1 ]
机构
[1] Univ Illinois, Coll Pharm, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
[2] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA USA
[3] Univ Southern Calif, Titus Family Dept Clin Pharm, Program Med & Publ Hlth, Sch Pharm, Los Angeles, CA USA
[4] Univ Southern Calif Angeles, USC Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA
[5] UIC Coll Pharm, 833S Wood St, Chicago, IL 60612 USA
关键词
claims analysis; HIV; nonoccupational postexposure prophylaxis; postexposure prophylaxis; trend analysis; HIV PREEXPOSURE PROPHYLAXIS; TENOFOVIR DF; RISK; PREVENTION; HEALTH; BOSTON; PREP; PEP; EMTRICITABINE; PERSPECTIVES;
D O I
10.1097/QAD.0000000000003701
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To describe national annual rates of nonoccupational postexposure prophylaxis (nPEP) in the United States.Design: Retrospective cohort study of commercially insured individuals in the Merative MarketScan Database from January 1, 2010 to December 31, 2019.Methods: Patients at least 13 years old prescribed nPEP per recommended Centers for Disease Control and Prevention guidelines were identified using pharmacy claims. Rates of use were described overall and stratified by sex, age group, and region. These rates were qualitatively compared to the diagnosis rates of human immunodeficiency virus (HIV) observed in the data. Joinpoint analysis identified inflection points of nPEP use.Results: Eleven thousand, three hundred and ninety-seven nPEP users were identified, with a mean age of 33.7 years. Most were males (64.6%) and lived in the south (33.2%) and northeast (32.4%). The rate of nPEP use increased 515%, from 1.42 nPEP users per 100 000 enrollees in 2010 to 8.71 nPEP users per 10 000 enrollees in 2019. The comparative nPEP use rates among subgroups largely mirrored their HIV diagnosis rates, that is, subgroups with a higher HIV rate had higher nPEP use. In the Joinpoint analysis significant growth was observed from 2012 to 2015 [estimated annual percentage change (EAPC): 45.8%; 95% confidence interval (CI): 29.4 - 64.3] followed by a more moderate increase from 2015 to 2019 (EAPC 16.0%; 95% CI: 12.6-19.6).Conclusions: nPEP use increased from 2010 to 2019, but not equally across all risk groups. Further policy interventions should be developed to reduce barriers and ensure adequate access to this important HIV prevention tool.
引用
收藏
页码:2223 / 2232
页数:10
相关论文
共 50 条
  • [31] Preexposure Prophylaxis in the United States: An Evolving HIV Prevention Opportunity
    Goldschmidt, Ronald H.
    [J]. CLINICAL INFECTIOUS DISEASES, 2017, 64 (02) : 150 - 151
  • [32] HIV and postexposure prophylaxis
    Benn, Paul
    Fisher, Martin
    [J]. CLINICAL MEDICINE, 2008, 8 (03) : 319 - 322
  • [33] Nonoccupational postexposure prophylaxis following sexual assault in industrialized low-HIV-prevalence countries: A review
    Draughon, Jessica E.
    Sheridan, Daniel J.
    [J]. PSYCHOLOGY HEALTH & MEDICINE, 2012, 17 (02) : 235 - 254
  • [34] Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston community health center
    Mayer, Kenneth H.
    Mimiaga, Matthew J.
    Cohen, Daniel
    Grasso, Chris
    Bill, Ronn
    VanDerwarker, Rodney
    Fisher, Alvan
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (04) : 494 - 499
  • [35] Choice of Antiretroviral Drugs for Postexposure Prophylaxis for Adults and Adolescents: A Systematic Review
    Ford, Nathan
    Shubber, Zara
    Calmy, Alexandra
    Irvine, Cadi
    Rapparini, Cristiane
    Ajose, Olawale
    Beanland, Rachel L.
    Vitoria, Marco
    Doherty, Meg
    Mayer, Kenneth H.
    [J]. CLINICAL INFECTIOUS DISEASES, 2015, 60 : S170 - S176
  • [36] Postexposure prophylaxis after sexual exposure to HIV
    Roland, Michelle E.
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2007, 20 (01) : 39 - 46
  • [37] Trends in the Number and Characteristics of HIV Pre-Exposure Prophylaxis Providers in the United States, 2014-2019
    Zhu, Weiming
    Huang, Ya-Lin A.
    Kourtis, Athena P.
    Hoover, Karen W.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 88 (03) : 282 - 289
  • [38] KNOWLEDGE OF PRE- AND POSTEXPOSURE PROPHYLAXIS FOR HIV PREVENTION AMONG INTERNAL MEDICINE RESIDENTS IN THE UNITED STATES
    Li, Lucy X.
    Lin, Jessica S.
    Tackett, Sean
    Bertram, Amanda
    Sisson, Stephen D.
    Rastegar, Darius
    Berkenblit, Gail
    [J]. AIDS EDUCATION AND PREVENTION, 2024, 36 (01) : 48 - 59
  • [39] Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure
    Mayer, Kenneth H.
    Gelman, Marcy
    Holmes, Johnathon
    Kraft, Jessica
    Melbourne, Kathleen
    Mimiaga, Matthew J.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2022, 90 (01) : 27 - 32
  • [40] HIV Postexposure Prophylaxis in an Urban Population of Female Sex Workers in Nairobi, Kenya
    Izulla, Preston
    McKinnon, Lyle R.
    Munyao, Julius
    Karanja, Sarah
    Koima, Winnie
    Parmeres, Joshua
    Kamuti, Solomon
    Kioko, Rosalia
    Nagelkerke, Nico
    Gakii, Gloria
    Wachihi, Charles
    Muraguri, Nicholas
    Musyoki, Helgar
    Gelmon, Lawrence
    Kaul, Rupert
    Kimani, Joshua
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 62 (02) : 220 - 225